Navigation Links
Innophos Holdings, Inc. Reports Second Quarter 2009 Results
Date:8/3/2009

trates for the three months ended June 30, 2009 the percentage changes in net sales by major product lines compared with the same period of the prior year, including the effect of price and volume/mix changes upon revenue:

                                         Price   Volume/Mix   Total
                                         -----   ----------   -----
    Purified Phosphoric Acid               4.3%     (60.5%)  (56.2%)
    Specialty Salts and Specialty Acids   36.5%     (35.1%)    1.4%
    STPP & Other Products                (44.3%)    (26.2%)  (70.5%)

Summary Cash Flow Statement

                     INNOPHOS HOLDINGS, INC. AND SUBSIDIARIES
           Condensed Consolidated Statements of Cash Flows (Unaudited)
                              (Dollars in thousands)

                                                       Six months   Six months
                                                          ended        ended
                                                         June 30,    June 30,
                                                            2009        2008
                                                            ----        ----
    Cash flows from operating activities
      Net income                                         $47,853     $68,543
      Adjustments to reconcile net income to net cash
       provided from operating activities:
        Depreciation and amortization                     23,849      27,139
        Amortization of deferred financing charges         2,269       1,365
        Deferred income tax provision (benefit)            3,473      (1,351)
        Deferred profit sharing                             (230)        462
        Share-based compensation                           1,219       1,453
        Gain on retirement of bonds                       (3,500)          -
      Changes in assets
'/>"/>
SOURCE Innophos Holdings, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related medicine news :

1. Innophos Holdings, Inc. Schedules Call to Discuss First Quarter 2009 Results
2. Innophos Holdings, Inc. Declares Quarterly Dividend
3. Innophos Holdings, Inc. Elects John M. Steitz as New Independent Director
4. JAG Media Holdings, Inc. Announces Completion of Acquisition of CardioGenics Inc.
5. Duane Reade Holdings, Inc. Announces Pricing of Offering of 11.75% Senior Secured Notes Due 2015
6. China Pharma Holdings, Inc. to Report Second Quarter 2009 Financial Results on August 12, 2009
7. Duane Reade Holdings, Inc. to Report Second Quarter 2009 Financial Results
8. SETO Holdings, Inc. Enters Into Two Additional Leases for Two New Hearing Centers in Maryland and Virginia
9. Duane Reade Holdings, Inc. Amends Terms and Extends Deadlines for Previously Announced Cash Tender Offers for Senior Secured Floating Rate Notes and Senior Subordinated Notes
10. Eastern Insurance Holdings, Inc. to Release 2nd Quarter 2009 Financial Results
11. Hill-Rom Holdings, Inc. Invites You to Join Its Fiscal 2009 Third Quarter Earnings Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2015)... , ... September 01, 2015 , ... ... delivery options, Blue Cross and Blue Shield of Minnesota (Blue Cross) has announced ... , Based in San Francisco, Doctor On Demand provides immediate access to ...
(Date:9/1/2015)... ... September 01, 2015 , ... ... Vending Machine,” is still strongly maintaining her firm’s success in the hair care ... In her upcoming city-to-city tour, Ellis will be providing “Look and learn” live ...
(Date:9/1/2015)... , ... September 01, 2015 ... ... Background Screeners (NAPBS®) has announced that Edge Information Management has been ... the Background Screening Credentialing Council (BSCC). , “Achieving and maintaining this ...
(Date:9/1/2015)... ... September 01, 2015 , ... With former IBMers among its founding members, Inmar ... inception more than 35 years ago. A pilot program begun by the company in ... not just those intent on pursuing careers in these fields. The program is now ...
(Date:9/1/2015)... (PRWEB) , ... September 01, 2015 , ... Royal River ... new study that followed men and women for 19 years and found that, among ... did not take multivitamins. , The report is part of the September 2015 issue ...
Breaking Medicine News(10 mins):Health News:Blue Cross and Blue Shield of Minnesota names Doctor On Demand as preferred telehealth destination 2Health News:Blue Cross and Blue Shield of Minnesota names Doctor On Demand as preferred telehealth destination 3Health News:Beauty Entrepreneur creates hair extension smart machine and mobile app inspired by UBER technology 2Health News:Edge Information Management Granted Continued NAPBS Accreditation 2Health News:Edge Information Management Granted Continued NAPBS Accreditation 3Health News:Inmar Announces Program to Fuel Student Passion for STEM – with an Unconventional Twist 2Health News:New Study Finds Multivitamins Extend Life After Stroke, Retailer Reports 2
... UPMC Health Plan announced the,launch of a small ... small businesses -- UPMC Health Plan,s Small Business ... with 2 to 99,employees a high- quality, easy-to-implement ... tools, and a,dedicated account manager and customer service ...
... shows no link , THURSDAY, Oct. 18 (HealthDay News) -- ... or after exercise will not prevent muscle soreness, a new ... each involving from 10 to 30 people. , Nine of ... and the time spent stretching by participants varied from 40 ...
... and,Reported Diluted Earnings per Share Decreased 1% to $0.84. Diluted Earnings ... 2007 First Nine Months Worldwide Net Revenue Increased 10% to $16.6, ... Share, Before Certain Significant Items, Increased 10% ... to ...
... MITI ), a biopharmaceutical company focusing on ... treatment of cancer,inflammatory and autoimmune diseases, announced today ... Product Dossier (IMPD),for the conduct of a phase ... lymphoblastic leukemia (ALL) in Germany. MT103, a BiTE(R) ...
... 2,200-plus healthcare professionals and exhibitors registered for the,first-ever ... CHICAGO, Oct. 17 With studies from ... of students and,adults enrolling in distance education in ... Information and Management Systems Society (HIMSS),will host its ...
... Our ... Telemedicine Product Line, SUN VALLEY, Calif., Oct. 18 ... new,Bluetooth(R) enabled telemedicine products to their line of disease,management solutions for ... "The addition of A & D,s Bluetooth(R) enabled Blood Pressure ...
Cached Medicine News:Health News:UPMC Health Plan Launches New Product for Small Businesses 2Health News:Wyeth Reports Earnings Results for the 2007 Third Quarter and First Nine Months 2Health News:Wyeth Reports Earnings Results for the 2007 Third Quarter and First Nine Months 3Health News:Wyeth Reports Earnings Results for the 2007 Third Quarter and First Nine Months 4Health News:Wyeth Reports Earnings Results for the 2007 Third Quarter and First Nine Months 5Health News:Wyeth Reports Earnings Results for the 2007 Third Quarter and First Nine Months 6Health News:Wyeth Reports Earnings Results for the 2007 Third Quarter and First Nine Months 7Health News:Wyeth Reports Earnings Results for the 2007 Third Quarter and First Nine Months 8Health News:Wyeth Reports Earnings Results for the 2007 Third Quarter and First Nine Months 9Health News:Wyeth Reports Earnings Results for the 2007 Third Quarter and First Nine Months 10Health News:Wyeth Reports Earnings Results for the 2007 Third Quarter and First Nine Months 11Health News:Wyeth Reports Earnings Results for the 2007 Third Quarter and First Nine Months 12Health News:Wyeth Reports Earnings Results for the 2007 Third Quarter and First Nine Months 13Health News:Micromet Receives Regulatory Approval to Conduct a Phase 2 Clinical Trial Investigating MT103 (MEDI-538) in Patients with Acute Lymphoblastic Leukemia 2Health News:Micromet Receives Regulatory Approval to Conduct a Phase 2 Clinical Trial Investigating MT103 (MEDI-538) in Patients with Acute Lymphoblastic Leukemia 3Health News:Micromet Receives Regulatory Approval to Conduct a Phase 2 Clinical Trial Investigating MT103 (MEDI-538) in Patients with Acute Lymphoblastic Leukemia 4Health News:Micromet Receives Regulatory Approval to Conduct a Phase 2 Clinical Trial Investigating MT103 (MEDI-538) in Patients with Acute Lymphoblastic Leukemia 5Health News:HIMSS' Second Virtual Conference & Expo Less Than a Month Away 2Health News:HIMSS' Second Virtual Conference & Expo Less Than a Month Away 3Health News:HIMSS' Second Virtual Conference & Expo Less Than a Month Away 4Health News:XTend Medical (XDMC) Adds New Bluetooth(R) Telemedicine Products From A&D Medical 2
(Date:9/1/2015)... Calif. and BRUSSELS ... AMGN ) and UCB (Euronext Brussels: UCB) today ... evaluating effect of RomosozUmab Compared with Teriparatide in ... fracture pReviously treated with bisphosphonatE therapy). The study ... significant difference in favor of romosozumab in the ...
(Date:9/1/2015)... , Sept. 1, 2015 Konica Minolta Medical ... Radiography (CR) system, designed to deliver enterprise level imaging ... the same Control Station as the Konica Minolta AeroDR ... an upgrade path from CR to DR. The SIGMA ... help improve workflow with unparalleled reliability and high capacity ...
(Date:9/1/2015)... DALLAS , Sept. 1, 2015 UT ... and distinguished faculty members joined U.S. Representatives ... in a roundtable discussion on the 21 st ... biomedical research currently being considered by the ... faculty – including National Academy of Sciences members, department ...
Breaking Medicine Technology:Amgen And UCB Announce Positive Top-Line Results From Open-Label Phase 3 Study Of Romosozumab Compared With Teriparatide 2Amgen And UCB Announce Positive Top-Line Results From Open-Label Phase 3 Study Of Romosozumab Compared With Teriparatide 3Amgen And UCB Announce Positive Top-Line Results From Open-Label Phase 3 Study Of Romosozumab Compared With Teriparatide 4Amgen And UCB Announce Positive Top-Line Results From Open-Label Phase 3 Study Of Romosozumab Compared With Teriparatide 5Amgen And UCB Announce Positive Top-Line Results From Open-Label Phase 3 Study Of Romosozumab Compared With Teriparatide 6Amgen And UCB Announce Positive Top-Line Results From Open-Label Phase 3 Study Of Romosozumab Compared With Teriparatide 7Amgen And UCB Announce Positive Top-Line Results From Open-Label Phase 3 Study Of Romosozumab Compared With Teriparatide 8Amgen And UCB Announce Positive Top-Line Results From Open-Label Phase 3 Study Of Romosozumab Compared With Teriparatide 9Konica Minolta Launches New CR System with Low-Cost Upgrade Path to DR 2U.S. Rep. Michael C. Burgess, M.D., hosts roundtable at UT Southwestern to discuss pivotal 21st Century Cures Act and future of biomedical science 2U.S. Rep. Michael C. Burgess, M.D., hosts roundtable at UT Southwestern to discuss pivotal 21st Century Cures Act and future of biomedical science 3U.S. Rep. Michael C. Burgess, M.D., hosts roundtable at UT Southwestern to discuss pivotal 21st Century Cures Act and future of biomedical science 4U.S. Rep. Michael C. Burgess, M.D., hosts roundtable at UT Southwestern to discuss pivotal 21st Century Cures Act and future of biomedical science 5
... PORTSMOUTH, N.H., Aug. 4, 2011 Novocure, a ... it has entered into a long-term supply agreement ... engineering and manufacturing conglomerate ITT Corporation (NYSE: ITT). ... ceramic components used to manufacture the disposable electrodes ...
... , Inc. (NASDAQ: PHMD ), an innovator ... offer*  to assist the families of children ... National Psoriasis Awareness Month in August (and continuing ... to afford treatments, will have their XTRAC® Excimer Laser ( ...
Cached Medicine Technology:Novocure Announces Long-Term Supply Agreement With ITT Corporation for Ceramic Sensor Technology 2Novocure Announces Long-Term Supply Agreement With ITT Corporation for Ceramic Sensor Technology 3PhotoMedex Covers XTRAC Laser Treatment Co-Pay for Children with Psoriasis 2PhotoMedex Covers XTRAC Laser Treatment Co-Pay for Children with Psoriasis 3PhotoMedex Covers XTRAC Laser Treatment Co-Pay for Children with Psoriasis 4
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: